12,125.90133.4
Stock Analysis, IPO, Mutual Funds, Bonds & More

Sell Strides Pharma, target Rs 375: Manas Jaiswal

Sell Strides Pharma at a price target of Rs 375 and a stoploss at Rs 406.

ETMarkets.com|
Last Updated: Jun 20, 2019, 08.47 AM IST
0Comments
Getty Images
GettyImages-664811618
Manas Jaiswal recommended to keep the stoploss at Rs 406.
Manas Jaiswal of manasjaiswal.com has a sell call on Strides Pharma with a target price of Rs 375. Time period given by analyst is Intra Day when Strides Pharma price can reach the defined target. Manas Jaiswal recommended to keep stoploss at Rs 406. Strides Pharma Science, incorporated in the year 1990, is a mid cap company (having a market cap of Rs 3544.37 crore) operating in pharmaceuticals and health care sector.

Strides Pharma Science key Products/Revenue Segments include Pharmaceuticals which contributed Rs 1270.91 crore to Sales Value (86.47 per cent of Total Sales), Other Operating Revenue which contributed Rs 111.92 crore to Sales Value (7.61 per cent of Total Sales), Sale of services which contributed Rs 36.46 crore to Sales Value (2.48 per cent of Total Sales), Royalty Income which contributed Rs 26.92 crore to Sales Value (1.83 per cent of Total Sales) and Export Incentives which contributed Rs 23.40 crore to Sales Value (1.59 per cent of Total Sales)for the year ending 31-Mar-2018.

For the quarter ended 31-03-2019, the company has reported a Consolidated sales of Rs 839.70 crore, up 5.69 per cent from last quarter Sales of Rs 794.50 crore and up 26.43 per cent from last year same quarter Sales of Rs 664.15 crore Company has reported net profit after tax of Rs 65.85 crore in latest quarter.

Also Read

Buy United Spirits, price target Rs 765: Manas Jaiswal

Buy Sun TV Network, price target Rs 535: Manas Jaiswal

Buy Balkrishna Industries, price target Rs 1,200: Manas Jaiswal

Buy GAIL (India), price target Rs 139: Manas Jaiswal

Buy Ashok Leyland, price target Rs 90: Manas Jaiswal

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service